Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of GnRHa plus recombinant human growth hormone in girls with central precocious puberty or rapidly progressive puberty
ChiCTR1800017120Phase 4Recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of somatropin and gonadotropin-releasing hormone agonist in central precocious puberty (CPP) and precocious puberty, sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoints: Predicted adult height, Growth velocity and 10 more. Started Oct 2018; status: recruiting.
02
Drugs
somatropingonadotropin-releasing hormone agonist
03
Conditions
central precocious puberty (CPP)precocious puberty
Beyond the preview
Go deeper on ChiCTR1800017120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017120.